Closed Trials

Ovary primary disease

AGO-OVAR 22 / YO 39523 (IMagyn050)

A Phase III, Multicenter, Randomized Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab for Patients with Newly-diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AGO-OVAR 20 / PAOLA-1

Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance

AGO-OVAR 18 / TRINOVA-3

Phase III trial

A phase 3 randomized, double-blind, placebo-controlled, multicenter study of AMG 386 with paclitaxel and carboplatin as first-line treatment of subjects with FIGO stage III-IV epithelial ovarian, primary peritoneal or fallopian tube cancers

AGO-OVAR 17

Phase III trial

A prospective randomized Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer. The BOOST (Bevacizumab Ovarian Optimal Standard Treatment) Trial

BOOST (Bevacizumab Ovarian Optimal Standard Treatment)

AGO-OVAR 16 / VEG110655

Phase III trial

A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AGO-OVAR 15

Phase II trial

An open-label, multicentre, randomized phase II study to compare the effects of Paclitaxel/Carboplatin and Lonafarnib to those of Paclitaxel/Carboplatin for first-line treatment of patients with epithelial ovarian cancer FIGO stages IIb – IV.

AGO-OVAR 12

Phase III trial

Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer.

AGO-OVAR 11

Phase III trial

A randomised, two-arm, multi-centre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer.

AGO-OVAR 10

Phase III trial

A randomized, double blind, placebo controlled, multicenre trial of Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response to first line chemotherapie.

AGO-OVAR 9

Phase III trial

A multi-national randomized Phase III GCIG Intergroup Study comparing 1st line chemotherapy with Gemcitabine, Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in previously untreated patients with epithelial ovarian cancer FIGO stages I – IV.

Ovary relapse therapy

AGO-OVAR 2.33 / ANITA

A phase III, randomized, double-blind trial of platinum-based chemotherapy followed by niraparib maintenance therapy with or without atezolizumab in patients with ovarian, tubal, or peritoneal carcinoma and a platinum-free treatment interval > 6 months

AGO-OVAR 2.31 / OReO

A randomized, double-blind, placebo-controlled, multicentre phase IIIb study on renewed maintenance therapy with olaparib in patients with epithelial ovarian cancer who were pretreated with a PARPi and respond to repeated platinum-based chemotherapy (OReO)

AGO-OVAR 2.30 / ATALANTE

A randomized, double blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab

AGO-OVAR 2.25 / GANNET53

A two-part, multicentre, international phase I and II trial assessing the safety and efficacy of the Hsp90 inhibitor ganetespib in combination with paclitaxel weekly in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer

AGO-OVAR 2.24 / MILO

A multinational, randomized, open-label phase 3 study of MEK162 vs. physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube or primary peritoneum.

AGO-OVAR 2.23 / SOLO2

Phase III trial

A phase III randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients who are in complete or partial response following platinum based chemotherapy.

AGO-OVAR 2.22 / NOVA

A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum sensitive ovarian cancer.

AGO-OVAR 2.21

A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. An ENGOT/GCIG Trial. Eine ENGOT/GCIG Studie.

AGO-OVAR 2.20 / PENELOPE

Phase III trial

A two-part, randomized Phase III, double-blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. Placebo plus standard chemotherapy in women with recurrent platinum resistant epithelial ovarian cancer and low HER3 mRNA expression

AGO-OVAR 2.19 / TRINOVA-2

Phase III trial

A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

AGO-OVAR 2.15 AURELIA / MO22224

Phase III trial

A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer

AGO-OVAR 2.12

Phase III trial

HECTOR (Hycamtin plus Carboplatin versus Established Regimens for the Treatment of Ovarian Cancer Relapse)

AGO-OVAR 2.11

Phase II trial

A randomized multicentre trial with SU11248 to evaluate dosage, schedule, tolerability, toxicity and effectiveness of al multitargeted receptor tyrosine kinase inhibitor monotherapie.

AGO-OVAR 2.10

Phase IIa trial

Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody removab® (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients.

AGO-OVAR 2.10

Phase IIa trial

Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody removab® (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients.

AGO-OVAR 2.9

Phase III trial

A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX®) and Carboplatin vs Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Cancer in Late Relapse (>6 months).

AGO-OVAR 2.7

Phase III trial

Reinduction therapy with paclitaxel and carboplatin plus epoetin alfa versus reinduction therapy with paclitaxel and carboplatin in recurrent platinum-sensitive ovarian cancer.

AGO-OVAR 2.3

Phase III trial

Topotecan versus Treosulfan in der Rezidivtherapie von Patientinnen mit Ovarialkarzinom nach Platin-/Paclitaxelvorbehandlung.

AGO-PRO 1 / Symptom Benefit

Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer?

AGO-TR 1 / BRCA-Screening

Incidence of BRCA in tumor samples in Ovarian Cancer Patients with primary or platinum sensitive recurrent ovarian cancer and correlation with germline status

UTERUS

AGO-EN 3 / RUBY

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY)

AtTEnd – Atezolizumab in endometrial carcinoma

A phase III, double-blind, randomized, placebo-controlled trial of the use of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial carcinoma

AGO-GYN 9 / ALIENOR

A multi-centre, randomized, open label, phase II trial of Bevacizumab plus weekly Paclitaxel then Bevacizumab monotherapy in maintenance versus weekly Paclitaxel then observation in patients with relapsed ovarian sex-cord stromal tumours

AGO-GYN 8

Efficacy, tolerability and safety of Temsirolimus in women with platinum-refractory ovarian carcinoma or advanced endometrial carcinoma

AGO-GYN 7

Phase II trial

Use of PegLiposomal doxorubicin (PLD) and carboplatin combination chemotherapy in gynecologic sarcomas and mixed mesenchymal tumors

AGO-GYN 6

Phase I/II trial

Feasibility Study of Pazopanib in Combination With Chemo in Gyn Tumors.

AGO-GYN 5

Phase II trial

Efficacy and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin, in women with LHRH receptor positive gynecological tumors.

AGO-GYN 4

Phase I trial

A phase I open label dose escalation study of oral treatment with BIBF 1120 in combination with standard treatment of paclitaxel and carboplatin in patients with advanced gynaecological malignancies.

VULVA

AGO-VOP.1 CaRE

Chemo and Radiotherapy in Epithelial Vulvar Cancer

CERVIX

AGO-ZX 3 / BEATcc

A randomized phase III study comparing chemotherapy with platinum and paclitaxel in combination with bevacizumab and atezolizumab versus chemotherapy with platinum and paclitaxel in combination with bevacizumab alone in patients with metastatic (FIGO IVB), persistent or recurrent cervical cancer

Clinical trials in surgical settings

AGO-OVAR OP.8 SHAPE

A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer

AGO-OVAR OP.7 TRUST / AGO-OVAR 19

Trial on radical upfront surgery in advanced ovarian cancer

Extension for Germany with evaluation of fragility and long-term quality of life

AGO-OVAR OP.4 / DESKTOP III

A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer

AGO-OVAR OP.3 / LION

The role of lymphadnectomy in advanced ovarian cancer

AGO-OVAR OP.2 / DESKTOP II

Validation of a score of predictive factors for complete resection in paltium-sensitive ovarian cancer.

PPE (Palmo-Plantar-Erythrodysesthesia)

AGO-PRO 2 / Mapisal

Treatment of Palmar-Plantar Erythrodysesthesia (PPE) in gynecologic oncology with Mapisal – an interventional, prospective, randomized, double-blind, placebo-controlled intergroup trial of the AGO and NOGGO Study Group